

IN THE CLAIMS:

Please amend the claims as follows:

Claims 1-2 (Canceled).

Claim 3 (Currently Amended): A recombinant antibody having an activity of recognizing GM1 ganglioside-bound amyloid β -protein and inhibiting the formation of amyloid fibrils, the antibody being IgG or Fab ~~IgG, Fab, Fab', F(ab')₂, scFv, or dsFv~~, comprising: a heavy chain variable region, and a light chain variable region; wherein the heavy chain variable region comprises ~~complementary complementarity~~ determining regions (CDRs) described in g), h) and i), and the light chain variable region comprises CDRs described in j), k) and l);

- g) CDR 1 consisting of an amino acid sequence of SEQ ID NO. 1;
- h) CDR 2 consisting of an amino acid sequence of SEQ ID NO. 2;
- i) CDR 3 consisting of an amino acid sequence of SEQ ID NO. 3;
- j) CDR 1 consisting of an amino acid sequence of SEQ ID NO. 4;
- k) CDR 2 consisting of an amino acid sequence of SEQ ID NO. 5; and
- l) CDR 3 consisting of an amino acid sequence of SEQ ID NO. 6.

Claim 4 (Previously Presented): The antibody according to claim 3, wherein the heavy chain variable region comprises an amino acid sequence of SEQ ID NO: 7.

Claim 5 (Previously Presented): The antibody according to claim 3, wherein the light chain variable region comprises an amino acid sequence of SEQ ID NO: 8.

Claim 6 (Previously Presented): The antibody according to claim 3, wherein the heavy chain variable region comprises an amino acid sequence of SEQ ID NO: 7; and the light chain variable region comprises an amino acid sequence of SEQ ID NO: 8.

Claim 7 (Previously Presented): The antibody according to claim 3, which is a humanized antibody.

Claims 8-31 (Canceled).